...
首页> 外文期刊>Cellular immunology >Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19
【24h】

Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19

机译:重新用毒治疗Covid-19的作用机制评价

获取原文
获取原文并翻译 | 示例
           

摘要

Coronavirus disease 2019 (COVID-19) is a global health emergency caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The rapid worldwide spread of SARS-CoV-2 infection has necessitated a global effort to identify effective therapeutic strategies in the absence of vaccine. Among the re-purposed drugs being tested currently, hydroxychloroquine (HCQ), without or with zinc ion (Zn++) and the antibiotic azithromycin (AZM), has been administered to prevent or treat patients with COVID-19. The outcome of multiple clinical studies on HCQ has been mixed. Zn++ interferes with viral replication by inhibiting replicative enzymes and its entry into cells may be facilitated by HCQ. Another immunomodulatory drug, methotrexate (MTX), is well known for its ability to mitigate overactive immune system by upregulating the anti-inflammatory protein, A20. However, its beneficial effect in treating COVID-19 has not drawn much attention. This review provides an overview of the virology of SARS-CoV-2 and an analysis of the mechanisms by which these anti-inflammatory agents may act in the treatment of COVID-19 patients. We propose a rationale for the combinatorial use of these re-purposed drugs that may help to combat this ongoing pandemic health emergency.
机译:2019年冠状病毒病(COVID-19)是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的全球卫生紧急情况。SARS-CoV-2感染在全球范围内迅速传播,这就需要全球努力在缺乏疫苗的情况下确定有效的治疗策略。2019冠状病毒疾病患者中,目前已被检测的药物中,已使用羟基喹啉(HCQ),不含锌离子或锌离子(AgM),抗生素阿奇霉素(AZM),以预防或治疗COVID-19患者。关于HCQ的多项临床研究结果好坏参半。锌通过抑制复制酶干扰病毒复制,HCQ可能促进其进入细胞。另一种免疫调节药物甲氨蝶呤(MTX)因其通过上调抗炎蛋白A20来缓解过度活跃的免疫系统而闻名。然而,2019冠状病毒疾病治疗的有益效果尚未引起广泛关注。2019冠状病毒疾病的病毒学研究和这些抗炎药可能在COVID-19患者治疗中的作用机制的分析。我们提出了组合使用这些重新设计的药物的理由,这些药物可能有助于对抗这一正在发生的大流行性卫生紧急情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号